nach oben

European Journal of Nuclear Medicine and Molecular Imaging

Erschienen in:

01.12.2007 | Original Article

TNM staging with FDG-PET/CT in patients with primary head and neck cancer

verfasst von: Patrick Veit-Haibach, Christopher Luczak, Isabel Wanke, Markus Fischer, Thomas Egelhof, Thomas Beyer, Gerlinde Dahmen, Andreas Bockisch, Sandra Rosenbaum, Gerald Antoch

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 12/2007

Einloggen, um Zugang zu erhalten

Abstract

Purpose

PET/CT, PET+CT, and CT were compared concerning accuracies in TNM staging and malignancy detection in head and neck cancer. The impact of PET/CT compared to the other imaging modalities on therapy management was assessed.

Materials and methods

Fifty-five patients with suspected head and neck primary cancer underwent whole-body FDG-PET/CT. PET/CT and PET+CT were evaluated by a nuclear medicine physician and a radiologist; CT was evaluated by two radiologists, PET by two nuclear physicians. Histopathology served as the standard of reference. Differences between the staging modalities were tested for statistical significance by McNemar’s test.

Results

Overall TNM-staging and T-staging with PET/CT were more accurate than PET+CT and CT alone (p < 0.05). PET/CT was marginally more accurate than CT alone in N-staging (p = 0.04); no statistically significant difference was found when compared to PET+CT for N-staging. PET/CT altered further treatment in 13 patients compared to CT only and in 7 patients compared to PET+CT.

Conclusion

Combined PET/CT proved to be partly more accurate in assessing the overall TNM-stage than CT and PET+CT. These results were based on a higher accuracy concerning the T-stage, mainly in patients with metallic implants and marginally the N-stage. Therapy decisions have been influenced in a substantial number of patients. PET/CT might be considered as a first line diagnostic tool in patients with suspected primary head and neck cancer.

Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55(1):10–30.PubMedCrossRef

NCCN. http://www.nccn.org. In: National Comprehensive Cancer Network.

Caponigro F, Milano A, Basile M, Ionna F, Iaffaioli RV. Recent advances in head and neck cancer therapy: the role of new cytotoxic and molecular-targeted agents. Curr Opin Oncol 2006;18(3):247–52.PubMedCrossRef

Cohen EE, Rosen F, Stadler WM, Recant W, Stenson K, Huo D, et al. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 2003;21(10):1980–7.PubMedCrossRef

Colevas AD. Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2006;24(17):2644–52.PubMedCrossRef

AWMF. http://www.awmf-online.de.

ESMO. http://www.esmo.org. In.

Pauleit D, Zimmermann A, Stoffels G, Bauer D, Risse J, Fluss MO, et al. 18F-FET PET Compared with 18F-FDG PET and CT in Patients with Head and Neck Cancer. J Nucl Med 2006;47(2):256–61.PubMed

Wong WL, Saunders M. The impact of FDG PET on the management of occult primary head and neck tumours. Clin Oncol (R Coll Radiol) 2003;15(8):461–6.

10.

Yousem DM, Montone KT. Head and neck lesions. Radiologic-pathologic correlations. Radiol Clin North Am 1998;36(5):983–1014, vii.PubMedCrossRef

11.

Kau RJ, Alexiou C, Laubenbacher C, Werner M, Schwaiger M, Arnold W. Lymph node detection of head and neck squamous cell carcinomas by positron emission tomography with fluorodeoxyglucose F 18 in a routine clinical setting. Arch Otolaryngol Head Neck Surg 1999;125(12):1322–8.PubMed

12.

Wong WLCE, McGurk M, Hussain K, Davis J, Beaney R, Baddeley H, et al. A prospective study of PET-FDG imaging for the assessment of head and neck squamous cell carcinoma. Clin Otolaryngol Allied Sci 1997;22(3):209–14.:209–14.PubMedCrossRef

13.

Branstetter BFt, Blodgett TM, Zimmer LA, Snyderman CH, Johnson JT, Raman S, et al. Head and neck malignancy: is PET/CT more accurate than PET or CT alone? Radiology 2005;235(2):580–6.PubMedCrossRef

14.

Goshen E, Davidson T, Yahalom R, Talmi YP, Zwas ST. PET/CT in the evaluation of patients with squamous cell cancer of the head and neck. Int J Oral Maxillofac Surg 2006;35(4):332–6.PubMedCrossRef

15.

Ha PK, Hdeib A, Goldenberg D, Jacene H, Patel P, Koch W, et al. The role of positron emission tomography and computed tomography fusion in the management of early-stage and advanced-stage primary head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2006;132(1):12–6.PubMedCrossRef

16.

Schoder H, Carlson DL, Kraus DH, Stambuk HE, Gonen M, Erdi YE, et al. 18F-FDG PET/CT for detecting nodal metastases in patients with oral cancer staged N0 by clinical examination and CT/MRI. J Nucl Med 2006;47(5):755–62.PubMed

17.

Antoch G, Jentzen W, Freudenberg LS, Stattaus J, Mueller SP, Debatin JF, et al. Effect of oral contrast agents on computed tomography-based positron emission tomography attenuation correction in dual-modality positron emission tomography/computed tomography imaging. Invest Radiol 2003;38(12):784–9.PubMed

18.

Antoch G, Kuehl H, Kanja J, Lauenstein TC, Schneemann H, Hauth E, et al. Dual-modality PET/CT scanning with negative oral contrast agent to avoid artifacts: introduction and evaluation. Radiology 2004;230(3):879–85.PubMedCrossRef

19.

Beyer T, Antoch G, Blodgett T, Freudenberg LF, Akhurst T, Mueller S. Dual-modality PET/CT imaging: the effect of respiratory motion on combined image quality in clinical oncology. Eur J Nucl Med Mol Imaging 2003;30(4):588–96.PubMedCrossRef

20.

Beyer T, Tellmann L, Nickel I, Pietrzyk U. On the use of positioning aids to reduce misregistration in the head and neck in whole-body PET/CT studies. J Nucl Med 2005;46(4):596–602.PubMed

21.

Biehl KJ, Kong FM, Dehdashti F, Jin JY, Mutic S, El Naqa I, et al. 18F-FDG PET definition of gross tumor volume for radiotherapy of non-small cell lung cancer: is a single standardized uptake value threshold approach appropriate? J Nucl Med 2006;47(11):1808–12.PubMed

22.

Drever L, Roa W, McEwan A, Robinson D. Iterative threshold segmentation for PET target volume delineation. Med Phys 2007;34(4):1253–65.PubMedCrossRef

23.

Delbeke D, Martin WH, Sandler MP, Chapman WC, Wright JK Jr, Pinson CW. Evaluation of benign vs malignant hepatic lesions with positron emission tomography. Arch Surg 1998;133(5):510–5; discussion 515–6.PubMedCrossRef

24.

Valk PE, Bailey DL, Townsend DW, Maisey MN. Positron Emission Tomography: Basic Science and Clinical Practice. London, Berlin, Heidelberg: Springer, 2003.

25.

AJCC. AJCC Cancer Staging Manual. 6 th. Edition ed. Stuttgart, Heidelberg, New York: Springer; 2002.

26.

Daisne JF, Duprez T, Weynand B, Lonneux M, Hamoir M, Reychler H, et al. Tumor volume in pharyngolaryngeal squamous cell carcinoma: comparison at CT, MR imaging, and FDG PET and validation with surgical specimen. Radiology 2004;233(1):93–100.PubMedCrossRef

27.

Tango T. Equivalence test and confidence interval for the difference in proportions for the paired-sample design. Stat Med 1998;17(8):891–908.PubMedCrossRef

28.

Adams S, Baum RP, Stuckensen T, Bitter K, Hor G. Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur J Nucl Med 1998;25(9):1255–60.PubMedCrossRef

29.

Schoder H, Yeung HW. Positron emission imaging of head and neck cancer, including thyroid carcinoma. Semin Nucl Med 2004;34(3):180–97.PubMedCrossRef

30.

Anzai Y, Carroll WR, Quint DJ, Bradford CR, Minoshima S, Wolf GT, et al. Recurrence of head and neck cancer after surgery or irradiation: prospective comparison of 2-deoxy-2-[F-18]fluoro-D-glucose PET and MR imaging diagnoses. Radiology 1996;200(1):135–41.PubMed

31.

Goerres GW, Schmid DT, Schuknecht B, Eyrich GK. Bone invasion in patients with oral cavity cancer: comparison of conventional CT with PET/CT and SPECT/CT. Radiology 2005;237(1):281–7.PubMedCrossRef

32.

Goerres GW, Von Schulthess GK, Hany TF. Positron emission tomography and PET CT of the head and neck: FDG uptake in normal anatomy, in benign lesions, and in changes resulting from treatment. AJR Am J Roentgenol 2002;179(5):1337–43.PubMed

33.

Nakamoto Y, Tatsumi M, Hammoud D, Cohade C, Osman MM, Wahl RL. Normal FDG distribution patterns in the head and neck: PET/CT evaluation. Radiology 2005;234(3):879–85.PubMedCrossRef

34.

Steinkamp HJ, Hosten N, Richter C, Schedel H, Felix R. Enlarged cervical lymph nodes at helical CT. Radiology 1994;191(3):795–8.PubMed

35.

Steinkamp HJ, Keske U, Schedel J, Hosten N, Felix R. The spiral CT of cervical lymph node enlargements. The initial clinical results. Rofo 1994;160(6):500–5.PubMed

36.

Connell A, Corry J, Milner AD, Hogg A, Hicks RJ, Rischin D, et al. Clinical impact of, and prognostic stratification by, F-18 FDG PET/CT in head and neck mucosal squamous cell carcinoma. Head Neck 2007.

37.

Wong WL, Hussain K, Chevretton E, Hawkes DJ, Baddeley H, Maisey M, et al. Validation and clinical application of computer-combined computed tomography and positron emission tomography with 2-[18F]fluoro-2-deoxy-D-glucose head and neck images. Am J Surg 1996;172(6):628–32.PubMedCrossRef

38.

Sanghera B, Wong WL, Lodge MA, Hain S, Stott D, Lowe J, et al. Potential novel application of dual time point SUV measurements as a predictor of survival in head and neck cancer. Nucl Med Commun 2005;26(10):861–7.PubMedCrossRef

39.

Gutzeit A, Antoch G, Kuhl H, Egelhof T, Fischer M, Hauth E, et al. Unknown primary tumors: detection with dual-modality PET/CT-initial experience. Radiology 2005;234(1):227–34.PubMedCrossRef

Titel: TNM staging with FDG-PET/CT in patients with primary head and neck cancer
verfasst von: Patrick Veit-Haibach
Christopher Luczak
Isabel Wanke
Markus Fischer
Thomas Egelhof
Thomas Beyer
Gerlinde Dahmen
Andreas Bockisch
Sandra Rosenbaum
Gerald Antoch
Publikationsdatum: 01.12.2007
Verlag: Springer-Verlag
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 12/2007
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-007-0564-5

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

TNM staging with FDG-PET/CT in patients with primary head and neck cancer

Abstract

Purpose

Materials and methods

Results

Conclusion

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Purpose

Materials and methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2007

The efficacy of whole-body FDG-PET or PET/CT for autoimmune pancreatitis and associated extrapancreatic autoimmune lesions

Pre- and post-synaptic sympathetic function in human hibernating myocardium

The added value of [18F]fluoro-L-DOPA PET in the diagnosis of hyperinsulinism of infancy: a retrospective study involving 49 children

[18F]FDG-PET predicts complete pathological response of breast cancer to neoadjuvant chemotherapy

Cerebral blood flow in temporal lobe epilepsy: a partial volume correction study

A new PET tracer specific for vascular endothelial growth factor receptor 2